Cryofibrinogenaemia with a good response to stanozolol.
We report a 63-year-old patient with an IgA-kappa multiple myeloma in complete remission who developed necrotic lesions on both ears and papular, purpuric lesions on his legs and cheeks. Initial differential diagnosis included perniosis and skin necrosis secondary to interferon treatment but subsequent investigation revealed cryofibrinogenaemia as the underlying cause. Stanozolol therapy, 2 mg/12 h, achieved a complete clearance of the skin lesions. Cryofibrinogenaemia is a disease which can be under-diagnosed unless it is considered in the work-up of a patient with thrombotic skin lesions. Stanozolol is useful as first line therapy for this disorder.
Revenga
F
F
Unit of Dermatology, Section of Haematology, Departments of Pathology and Biochemistry, Hospital General de Soria, Spain. frevenga@teleline.es
Aguilar
C
C
González
R
R
Paricio
J F
JF
Sanz
P
P
Santos
I
I
D045930:Anabolic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D003449:Cryoglobulinemia / Q000175:diagnosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D013197:Stanozolol / Q000627:therapeutic use*
D045930:Anabolic Agents; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D013197:Stanozolol